Table 1. Other public sector utilization of GeneXpert in 21 high tuberculosis (TB) burden countries (2016–2017).
| Country (WHO
classification) |
Use of NTP GeneXpert for
diagnosing other diseases (2017) |
Other programs procuring
GeneXpert machines (2016, 2017) |
Implementation of Xpert Ultra
cartridges in the public sector (2017) |
|---|---|---|---|
| South Africa | HCV VL, HIV-1 VL, HPV, NG/CT,
C Diff, Carba R, Influenza |
HIV | Procured and in use in the public
sector |
| India | No | NA | In discussion * |
| Tanzania | HCV-VL, HIV-1 VL, HIV-1 qual/EID | No | Procured and in use in the public
sector, plan to procure in 2018 (private sector) |
| Ethiopia | Piloting (HIV-1 qual/EID and HIV-1
VL) |
Yes | Plan to procure in 2018 |
| Kenya | No | No | Plan to procure in 2018 |
| Nigeria | HCV-VL, HIV-1 VL, HPV, NG/CT | HIV | Plan to procure in 2018 |
| Thailand | No | No | Do not have definitive plans |
| Myanmar | No | HIV, HCV | Procured but not yet in use in the public
sector # |
| Philippines | No | No | Do not have definitive plans |
| Mozambique | No | No | Plan to procure in 2018 |
| Pakistan | HCV VL, HIV-1 VL | No | Procured and in use in the public
sector |
| Cambodia | NA | NA | Plan to procure |
| Viet Nam | No | NA | Plan to procure in 2018 |
| Uganda | HIV-VL | NA | Plan to procure in 2018 |
| DR Congo | No | No | Do not have definitive plans |
| Brazil | No | No | Plan to procure in 2018 |
| Bangladesh | No | No | Do not have definitive plans |
| Russian Federation | NA | NA | Do not have definitive plans |
| Zimbabwe | HIV-1 VL, HIV-1 qual/EID | HIV | Procured, but not yet in use in the
public sector |
| Afghanistan | No | No | Plan to procure in 2018 |
| China | NA | NA | Do not have definitive plans |
WHO: World Health Organization; NTP: National tuberculosis programme; HCV-VL: Hepatitis-C virus- viral load; HIV-VL: human immunodeficiency virus- viral load; HPV: human papilloma virus; NG/CT: Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT); C Diff: Clostridium difficile; Carba R: Carbapenem resistance; Influenza: Detection of Flu A and Flu B with 2009 H1N1 Call Out; HIV-1 qual/EID: human immunodeficiency virus qualitative test/Early infant diagnosis; NA: not available; *India is currently discussing whether Xpert Ultra should be implemented within the public sector; # Myanmar is currently using Xpert Ultra in a prevalence survey.